HK Stock Market Move | REMEGEN (09995) rises over 3%; achieves a turnaround to profit in the first three quarters; previously signed an exclusive licensing agreement with AbbVie for RC148.

date
10:24 30/10/2026
avatar
GMT Eight
REMEGEN (09995) rose over 3% intraday. As of press time, it was up 2.92% at HK$65.2, with a turnover of HK$60.0548 million.
REMEGEN (09995) rose over 3% intraday, up 2.92% as of press time at HK$65.2, with turnover of HK$60.0548 million. On the news front, on October 29, REMEGEN released its Q3 2026 report. In the first three quarters, the company achieved operating revenue of RMB6.764 billion, up 293.28% year-on-year; net profit attributable to shareholders of the listed company was RMB5.273 billion, turning from loss to profit year-on-year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB4.412 billion; basic earnings per share were RMB9.41. In the first three quarters, the year-on-year increase in operating revenue was mainly due to higher sales volumes and increased sales revenue of Telitacicept for Injection and Disitamab Vedotin for Injection, while the company signed an exclusive licensing agreement with AbbVie for RC148, significantly increasing technology licensing revenue.